Diversified pharmaceutical company with divisions
for novel medicines and complex generics



ArborMed and BC World,Ltd. Announce Research Collaboration A…

페이지 정보

댓글 0건 조회 34회 작성일 22-11-18 14:57


Arbormed announced on May 25th that it has released the therapeutic potential of ARBM-201 for Acute Respiratory Distress Syndrome (ARDS), for the first time at the "American Thoracic Society 2022 (ATS 2022)" held in San Francisco from May 13th to 18th (local time).

Pendrin is an anion exchange protein located on the membrane, and is expressed in the inner ear, thyroid, and kidney. Pendrin expression in the lung is only present in patients with respiratory diseases such as ARDS, asthma, chronic obstructive pulmonary diseases, and allergic rhinitis. ARBM-201, a novel pendrin inhibitor, is developed as a first-in-class ARDS therapeutics that reduces the transport of thiocyanate ions and prevents formation of hypothiocyanite ions by blocking the pendrin activity and consequently leading to reduced inflammatory cytokines and lung damage.

Arbormed presented the effects of ARBM-201 on in vitro pendrin activity and the efficacy on LPS-induced lung injury model in mice at the scientific poster session accompanied by the oral session

ARBM-201 showed the lowest IC50 of anion exchange in pendrin among the publicly available pendrin inhibitors. ARBM-201 also suppressed the LPS-induced pendrin upregulation in human alveolar epithelial cells (hAEC).

ARBM-201 treatment at 1μg/kg of BID injection suppressed the pendrin expression in the lung of LPS-induced acute lung injury mouse model and significantly reduced the bronchioalveolar lavage fluid (BALF) total cell counts and protein level. ARBM-201 also highly reduced Inflammatory cytokines in BALF such as IL-1β, MIP-2, IL-6, TNF-α and improved the histopathology of the injured lung.

Currently, there is no effective treatment for ARDS, and steroids administered to patients in intensive care units (ICU) are known to have side effects with little therapeutic effects. In addition, ongoing ARDS-targeting clinical trials are failed or are expected to have additional trials to validate the therapeutic effects.

"Pendrin inhibition is expected to be more effective than drugs suppressing specific inflammatory targets, as it can control multiple inflammatory cytokines at the upstream of the inflammatory pathway," said CTO Weonbin Im and "ARBM-201 is currently in the nonclinical stage and aims to submit IND to MFDS(K-FDA) or FDA within the next two years.”


등록된 댓글이 없습니다.